Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins Today

09/21/2021 | 02:12am EDT

TOKYO , September 21, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has begun the pilot sales of an exercise support service, Fit-eNce HomeTM, designed under the supervision of NESTA JAPAN Inc. (President and Representative Director: Reki Higashiyama, "NESTA JAPAN") , to support people in performing science-based exercise programs*1 at home.

Exercise therapy is reported to be beneficial as a treatment for various diseases, including type 2 diabetes. However, it is often difficult for physicians to offer specific guidance on exercise therapies or to be aware of all of the exercises that a patient performs. Meanwhile, it is also difficult for patients to know what exercise programs are appropriate for them and to maintain the motivation to exercise, bringing challenges in starting and continuing exercise. In addition, since the spread of COVID-19 has reduced opportunities for exercise due to various changes in living environments, such as restrictions on going out and the permeation of remote work, maintaining and improving the frequency and quantity of exercise is considered an issue.

Fit-eNce HomeTM is a new exercise support service expected to solve these problems. It is designed to enable patients to continuously implement science-based exercise programs at home under the guidance of physicians. The exercise program provided by this service was developed, under the supervision of NESTA JAPAN, to be as frequent, intensive, and quantitative as the Fit-eNce®*2 exercise program, which was verified in medical and health research to be useful in improving the blood glucose control of type 2 diabetes patients.

Patients who have been referred to the service by a physician submit an application to enroll in it through a dedicated smartphone app and receive physician's approval for use of the service. Exercise programs consist of aerobic exercise and resistance exercise (repetitive exercises that exert resistance on target muscles). The aerobic exercises are performed using dedicated videos and heart rate meters, while the resistance exercises are performed using training tubes. Through online personal training, patients can receive advice from sports trainers on how to set the intensity and perform specific activities that fit their individual physical strength. Through a smartphone app, patients can share their exercise records with their physicians. Physicians can check the exercise records of their patients on a dedicated system and use it to monitor their patients' daily exercise and communicate with them, supporting them in continuing to exercise. Physicians can register with Fit-eNce® Healthcare Professional Website*3.

Fit-eNce®, an exercise support service to continually implement science-based exercise programs in fitness clubs, remains to be offered only in Kanagawa prefecture.

Fit-eNce® and Fit-eNce HomeTM were created with the aim of generating and providing evidence-based healthcare solutions through the integration of medicine and exercise as a part of Astellas' Rx+® Business*4. Astellas will continue to strive towards the realization of a society where appropriate exercise is practiced and people can live true to themselves, healthy in both mind and body.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 06:11:04 UTC.


© Publicnow 2021
All news about ASTELLAS PHARMA INC.
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
More news
Financials
Sales 2022 1 327 B 11 688 M 11 688 M
Net income 2022 196 B 1 723 M 1 723 M
Net cash 2022 584 B 5 142 M 5 142 M
P/E ratio 2022 18,4x
Yield 2022 2,55%
Capitalization 3 627 B 31 899 M 31 957 M
EV / Sales 2022 2,29x
EV / Sales 2023 2,05x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 957,50 JPY
Average target price 2 486,15 JPY
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.22.80%31 899
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979